#USA #Persistent Systems #Pune #NVIDIA #GenMoIVS

Persistent Systems Partners with NVIDIA for Breakthrough in Healthcare Research

Persistent Systems, a leader in Digital Engineering, recently announced a significant collaboration with NVIDIA, aimed at expediting innovation in the healthcare and life sciences sector. The partnership is set to harness advanced AI technologies to improve the landscape of computer-aided drug discovery and research outcomes.

In an era where healthcare corporations are under pressure to deliver new therapies swiftly, the integration of artificial intelligence is becoming essential for modern research methodologies. Persistent's deep knowledge and experience—combined with NVIDIA's robust AI platform—promise to facilitate the transition of AI experiments into practical applications within essential workflows. This seamless integration could transform how life sciences companies approach drug development, particularly by enabling them to operate more effectively in data-intensive, regulated environments.

The Role of GenMoIVS in Drug Discovery

One of the key innovations from this partnership is the introduction of the Generative Molecules and Virtual Screening solution (GenMoIVS), developed using NVIDIA's BioNeMo framework and the NeMo Agent Toolkit. This cutting-edge solution will allow for real-time, AI-driven simulations that realistically model molecular behaviors based on extensive domain-specific datasets.

GenMoIVS will empower researchers to optimize workflows, prioritize potential drug candidates, and enhance experimental designs without compromising scientific accuracy. This advance in drug discovery aims to reduce the risks associated with early-stage developments and decrease traditional testing cycles significantly while increasing success rates in clinical pipelines.

As Ganesh Nathella, Executive Vice President and General Manager of HLS Business at Persistent, indicated: "Healthcare and life sciences companies need to devise new therapies more rapidly. The traditional R&D cycle is often slow and labor-intensive. With GenMoIVS, we enable our BioPharma partners to transition to AI-guided discoveries within days instead of months, enabling continuous decision-making for virtual screening and experimental planning."

Maximizing Potential with AI

The services offered by Persistent under this collaboration include employing NVIDIA AI Enterprise for specific applications in biosciences, including preclinical research. By providing high-fidelity molecular simulations and expansive virtual screening capabilities, this partnership allows life sciences companies to engage in practical lab experiments backed by sophisticated simulations.

Additionally, the collaboration will lead to the development of industry-ready agent applications for computer-aided drug research, further enhancing the systems and capabilities that biopharmaceutical companies have at their disposal.

John Fanelli, Vice President of Enterprise Software at NVIDIA, remarked, "The healthcare and life sciences sectors are rapidly accelerating towards AI-powered research. Our extensive AI platform empowers Persistent to deliver production-grade agent-based systems for molecular simulations and virtual screening, meeting the urgent global demand for new therapies."

A Commitment to Sustainability and Innovation

Persistent Systems is not just focused on technological advancements; it is also invested in sustainability practices. The company operates with a commitment to carbon neutrality and social responsibility, becoming recognized as one of America’s leading workplaces for inclusivity and diversity. As Persistent continues to evolve and grow, it reinforces its position in the market with innovative solutions and a strong ethical framework.

Moving forward, Persistent plans to incorporate open NVIDIA Nemotron models to further enhance the GenMolVS solution. Moreover, the use of NVIDIA’s accelerated computing technology, servers, and microservices will underpin scalable and cost-effective application development, essential for deploying high-precision AI outcomes within varied business workflows.

Through this collaboration, Persistent aims not only to broaden its engineering capabilities in AI and large language models (LLMs) but also to offer its clients increasingly sophisticated data platforms.

In conclusion, the partnership between Persistent Systems and NVIDIA marks an important milestone in healthcare innovation. By merging AI advancements with drug discovery, the two companies are paving the way for faster, more effective therapeutic solutions that could significantly benefit both pharmaceutical companies and patients alike.